We previously demonstrated that expression levels of mdig, also known as mina53, NO52, JMJD10, and RIOX2, predicts survival outcomes of breast cancer patients, depending on the status of lymph node metastasis.22 For breast cancers without lymph node metastasis, higher levels of mdig predict poorer overall survival of breast cancer patients. Here, RIOX2 is linked to metastatic malignant neoplasm in the lymph nodes.